+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Generic Oncology Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 116 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5717610
Description Jump to:

Industry Outlook

The generic oncology drugs market is set to growth at a compounded annual growth rate (CAGR) of 6.1% during the forecast period from 2022 to 2030. According to the statistics provided by World Health Organization (WHO) in 2022, 9.6 million people worldwide have been estimated to be dead due to cancer. It is considered as the second leading cause of death, researchers are of the opinion that approximately 30% cancer deaths can be prevented by avoiding risk factors such as alcohol consumption, tobacco smoking, early diagnosis etc. Generic oncology drugs drastically reduce the healthcare cost burden associated with cancer treatment, but still there is ambiguity among healthcare professionals regarding its effectiveness and bioequivalence when compared to branded drugs. Healthcare agencies have made it imperative for pharmaceutical companies to follow ICH and cGMP guidelines while manufacturing generic oncology drugs.

Excellent pharmacokinetic and pharmacodynamic drug profile is related to the positive inclination among oncologist worldwide

Small molecule are currently dominating the oncology generic drugs market. They apparently constitute for 90% of the medicines currently available in the market. The chief parameters responsible for its popularity among oncologist throughout the globe are its excellent drug pharmacokinetic and pharmacodynamic profile. Large molecules comprises of biologics which are gaining huge traction in the current scenario as they resemble biomolecules present in the human body and specifically binds to those cell receptors which are associated with disease process resulting in high drug efficacy, safety and minimal side effects. Expiry of process patent of biologics employed in cancer treatment will create opportunity for its generic version to enter into market, thereby reducing cost burden associated with cancer.

Significant rise in cancer patients and increasing trend of generic substitution over branded drugs drive the market growth in North America

North America with a market share of 42% is the largest regional market for generic oncology drugs market. According to the research findings of Center for Disease Control and Prevention (CDC), the percent of adults diagnosed with cancer in the United States is 9.4%. The drivers associated with its dominance are rising prevalence of cancer and increasing trend of generic substitution over branded drugs, it is state specific in U.S. and province specific in Canada. Europe holds 30% market share on account of supportive regulatory scenario provided by European Medical Agency (EMA) for generic oncology drugs. Domicile of chief players such as Teva Pharmaceutical Industries, Ltd., Mylan N.V., Merck & Co., and Novartis A.G. further bolster the market growth in Europe. Asia Pacific represents 20% share owing to the significant rise in the number of patients diagnosed with cancer and booming oncology generic market receiving business leverage from government healthcare authorities to reduce the cost burden associated with cancer treatment.

Pharmaceutical giants having a strong foothold in the generic oncology drugs market are AstraZeneca, Plc., Bayer Healthcare AG., Celgene Corporation, F.Hoffman-La Roche Ltd., GlaxoSmithkline, Plc., Johnson and Johnson, Merck & Co., Mylan N.V., Novartis AG. and Teva Pharmaceutical Industries, Ltd.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Generic Oncology Drugs market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Generic Oncology Drugs market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Molecule

  • Small Molecule
  • Large Molecule

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Generic Oncology Drugs market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Generic Oncology Drugs market?
  • Which is the largest regional market for Generic Oncology Drugs market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Generic Oncology Drugs market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Generic Oncology Drugs market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Generic Oncology Drugs Market
2.2. Global Generic Oncology Drugs Market, By Molecule, 2021 (US$ Million)
2.3. Global Generic Oncology Drugs Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021

3. Generic Oncology Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Generic Oncology Drugs Market Vendors
3.2. Strategies Adopted by Generic Oncology Drugs Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030

4. Generic Oncology Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Generic Oncology Drugs Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis

5. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Small Molecule
5.3.2. Large Molecule

6. North America Generic Oncology Drugs Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
6.3.Generic Oncology Drugs Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)

7. UK and European Union Generic Oncology Drugs Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
7.3.Generic Oncology Drugs Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)

8. Asia Pacific Generic Oncology Drugs Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
8.3.Generic Oncology Drugs Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)

9. Latin America Generic Oncology Drugs Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
9.3.Generic Oncology Drugs Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)

10. Middle East and Africa Generic Oncology Drugs Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
10.3.Generic Oncology Drugs Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Generic Oncology Drugs Market: By Molecule, 2020-2030, USD (Million)

11. Company Profile
11.1. AstraZeneca, Plc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Bayer Healthcare AG.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Celgene Corporation
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. F.Hoffman-La Roche Ltd.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. GlaxoSmithKline, Plc.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Johnson and Johnson
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Merck & Co.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Mylan N.V.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Novartis AG.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Teva Pharmaceutical Industries, Ltd.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives

List of Figures
Figure 1 Global Generic Oncology Drugs Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Generic Oncology Drugs Market: Quality Assurance
Figure 5 Global Generic Oncology Drugs Market, By Molecule, 2021
Figure 6 Global Generic Oncology Drugs Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Generic Oncology Drugs Market, 2021
Figure 8 Market Positioning of Key Generic Oncology Drugs Market Players, 2021
Figure 9 Global Generic Oncology Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Generic Oncology Drugs Market, By Molecule, 2021 Vs 2030, %
Figure 11 U.S. Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 12 Canada Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 14 UK Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 15 Germany Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 16 Spain Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 17 Italy Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 18 France Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 20 China Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 21 Japan Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 22 India Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 23 Australia Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 24 South Korea Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 26 Brazil Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 27 Mexico Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 29 GCC Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 30 Africa Generic Oncology Drugs Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Generic Oncology Drugs Market (US$ Million), 2020 - 2030

List of Tables
Table 1 Global Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 2 North America Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 3 U.S. Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 4 Canada Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 5 Rest of North America Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 6 UK and European Union Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 7 UK Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 8 Germany Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 9 Spain Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 10 Italy Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 11 France Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 12 Rest of Europe Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 13 Asia Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 14 China Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 15 Japan Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 16 India Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 17 Australia Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 18 South Korea Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 19 Latin America Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 20 Brazil Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 21 Mexico Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 22 Rest of Latin America Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 23 Middle East and Africa Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 24 GCC Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 25 Africa Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)
Table 26 Rest of Middle East and Africa Generic Oncology Drugs Market By Molecule, 2020-2030, USD (Million)

Companies Mentioned

  • AstraZeneca
  • Plc.
  • Bayer Healthcare AG.
  • Celgene Corporation
  • F.Hoffman-La Roche Ltd.
  • GlaxoSmithkline Plc.
  • Johnson and Johnson
  • Merck & Co.
  • Mylan N.V.
  • Novartis AG.
  • Teva Pharmaceutical Industries Ltd.

Related Topics

Related Reports

Generic Oncology Drugs Global Market Report 2024 - Product Image

Generic Oncology Drugs Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Generic Oncology Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Generic Oncology Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 176 Pages
  • Global
Generic Oncology Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032 - Product Image

Generic Oncology Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032

  • Report
  • 145 Pages
  • Global
From
Generic Drugs - Global Strategic Business Report - Product Image

Generic Drugs - Global Strategic Business Report

  • Report
  • 711 Pages
  • Global
From
Global Generic Injectables Market by Product (Large Molecule Injectables, Small Molecule Injectables), Type (Cytokines, Insulin, Monoclonal Antibodies), Application, Distribution Channel - Forecast 2024-2030 - Product Image

Global Generic Injectables Market by Product (Large Molecule Injectables, Small Molecule Injectables), Type (Cytokines, Insulin, Monoclonal Antibodies), Application, Distribution Channel - Forecast 2024-2030

  • Report
  • 188 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.